173 related articles for article (PubMed ID: 16873055)
1. CK2 and PML: regulating the regulator.
Lallemand-Breitenbach V; de Thé H
Cell; 2006 Jul; 126(2):244-5. PubMed ID: 16873055
[TBL] [Abstract][Full Text] [Related]
2. A CK2-dependent mechanism for degradation of the PML tumor suppressor.
Scaglioni PP; Yung TM; Cai LF; Erdjument-Bromage H; Kaufman AJ; Singh B; Teruya-Feldstein J; Tempst P; Pandolfi PP
Cell; 2006 Jul; 126(2):269-83. PubMed ID: 16873060
[TBL] [Abstract][Full Text] [Related]
3. CK2 mediates phosphorylation and ubiquitin-mediated degradation of the PML tumor suppressor.
Scaglioni PP; Yung TM; Choi S; Baldini C; Konstantinidou G; Pandolfi PP
Mol Cell Biochem; 2008 Sep; 316(1-2):149-54. PubMed ID: 18566754
[TBL] [Abstract][Full Text] [Related]
4. Knocking down PML impairs p53 signaling transduction pathway and suppresses irradiation induced apoptosis in breast carcinoma cell MCF-7.
Bao-Lei T; Zhu-Zhong M; Yi S; Jun-Jie Q; Yan D; Hua L; Bin L; Guo-Wei Z; Zhi-Xian S
J Cell Biochem; 2006 Feb; 97(3):561-71. PubMed ID: 16215989
[TBL] [Abstract][Full Text] [Related]
5. Activation of protein kinase CK2 attenuates FOXO3a functioning in a PML-dependent manner: implications in human prostate cancer.
Chatterjee A; Chatterjee U; Ghosh MK
Cell Death Dis; 2013 Mar; 4(3):e543. PubMed ID: 23492774
[TBL] [Abstract][Full Text] [Related]
6. Viral disruption of promyelocytic leukemia (PML) nuclear bodies by hijacking host PML regulators.
Frappier L
Virulence; 2011; 2(1):58-62. PubMed ID: 21217204
[TBL] [Abstract][Full Text] [Related]
7. Direct transcriptional activation of promyelocytic leukemia protein by IFN regulatory factor 3 induces the p53-dependent growth inhibition of cancer cells.
Kim TK; Lee JS; Oh SY; Jin X; Choi YJ; Lee TH; Lee Eh; Choi YK; You S; Chung YG; Lee JB; DePinho RA; Chin L; Kim H
Cancer Res; 2007 Dec; 67(23):11133-40. PubMed ID: 18056437
[TBL] [Abstract][Full Text] [Related]
8. Hepatitis C virus core protein inhibits tumor suppressor protein promyelocytic leukemia function in human hepatoma cells.
Herzer K; Weyer S; Krammer PH; Galle PR; Hofmann TG
Cancer Res; 2005 Dec; 65(23):10830-7. PubMed ID: 16322229
[TBL] [Abstract][Full Text] [Related]
9. Functional polymorphism of the CK2alpha intronless gene plays oncogenic roles in lung cancer.
Hung MS; Lin YC; Mao JH; Kim IJ; Xu Z; Yang CT; Jablons DM; You L
PLoS One; 2010 Jul; 5(7):e11418. PubMed ID: 20625391
[TBL] [Abstract][Full Text] [Related]
10. AXIN is an essential co-activator for the promyelocytic leukemia protein in p53 activation.
Li Q; He Y; Wei L; Wu X; Wu D; Lin S; Wang Z; Ye Z; Lin SC
Oncogene; 2011 Mar; 30(10):1194-204. PubMed ID: 21057547
[TBL] [Abstract][Full Text] [Related]
11. The SUMO E3-ligase PIAS1 regulates the tumor suppressor PML and its oncogenic counterpart PML-RARA.
Rabellino A; Carter B; Konstantinidou G; Wu SY; Rimessi A; Byers LA; Heymach JV; Girard L; Chiang CM; Teruya-Feldstein J; Scaglioni PP
Cancer Res; 2012 May; 72(9):2275-84. PubMed ID: 22406621
[TBL] [Abstract][Full Text] [Related]
12. Evidence for a role of the cellular ND10 protein PML in mediating intrinsic immunity against human cytomegalovirus infections.
Tavalai N; Papior P; Rechter S; Leis M; Stamminger T
J Virol; 2006 Aug; 80(16):8006-18. PubMed ID: 16873257
[TBL] [Abstract][Full Text] [Related]
13. [Increase of BIRC5 gene expression in non-small cell lung cancer and esophageal squamous cell carcinoma does not correlate with expression of genes SMAC/DIABLO and PML encoding its inhibitors].
Vaĭshlia NA; Zinov'eva MV; Sass AV; Kopantsev EP; Vinogradova TV; Sverdlov ED
Mol Biol (Mosk); 2008; 42(4):652-61. PubMed ID: 18856066
[TBL] [Abstract][Full Text] [Related]
14. Promyelocytic leukemia nuclear bodies are predetermined processing sites for damaged DNA.
Bøe SO; Haave M; Jul-Larsen A; Grudic A; Bjerkvig R; Lønning PE
J Cell Sci; 2006 Aug; 119(Pt 16):3284-95. PubMed ID: 16868026
[TBL] [Abstract][Full Text] [Related]
15. The role of PML in tumor suppression.
Salomoni P; Pandolfi PP
Cell; 2002 Jan; 108(2):165-70. PubMed ID: 11832207
[TBL] [Abstract][Full Text] [Related]
16. Epstein-Barr virus nuclear antigen 1 Hijacks the host kinase CK2 to disrupt PML nuclear bodies.
Sivachandran N; Cao JY; Frappier L
J Virol; 2010 Nov; 84(21):11113-23. PubMed ID: 20719947
[TBL] [Abstract][Full Text] [Related]
17. PML RING suppresses oncogenic transformation by reducing the affinity of eIF4E for mRNA.
Cohen N; Sharma M; Kentsis A; Perez JM; Strudwick S; Borden KL
EMBO J; 2001 Aug; 20(16):4547-59. PubMed ID: 11500381
[TBL] [Abstract][Full Text] [Related]
18. RNF4 is a poly-SUMO-specific E3 ubiquitin ligase required for arsenic-induced PML degradation.
Tatham MH; Geoffroy MC; Shen L; Plechanovova A; Hattersley N; Jaffray EG; Palvimo JJ; Hay RT
Nat Cell Biol; 2008 May; 10(5):538-46. PubMed ID: 18408734
[TBL] [Abstract][Full Text] [Related]
19. Promyelocytic leukemia-nuclear body formation is an early event leading to retinoic acid-induced differentiation of neuroblastoma cells.
Delaune A; Corbière C; Benjelloun FD; Legrand E; Vannier JP; Ripoll C; Vasse M
J Neurochem; 2008 Jan; 104(1):89-99. PubMed ID: 17986232
[TBL] [Abstract][Full Text] [Related]
20. PML inhibits HIF-1alpha translation and neoangiogenesis through repression of mTOR.
Bernardi R; Guernah I; Jin D; Grisendi S; Alimonti A; Teruya-Feldstein J; Cordon-Cardo C; Simon MC; Rafii S; Pandolfi PP
Nature; 2006 Aug; 442(7104):779-85. PubMed ID: 16915281
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
